Baxter International June 15th Short Interest Update

Baxter International (NYSE:BAX), A drop of 33,222,745 shares or 43.4% was seen in the short interest of Baxter International. Even as the interest dropped from 76,526,696 shares on May 31,2016 to 43,303,951 shares on June 15,2016, the days to cover came in at 11. The updated interest stood at 7.9% of the stocks floats. The stock has seen an average daily volume of 4,071,727 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Baxter International (NYSE:BAX): The stock opened at $44.84 on Friday but the bulls could not build on the opening and the stock topped out at $44.84 for the day. The stock traded down to $43.72 during the day, due to lack of any buying support eventually closed down at $43.85 with a loss of -4.59% for the day. The stock had closed at $45.96 on the previous day. The total traded volume was 11,204,951 shares.

The company shares have rallied 14.26% from its 1 Year high price. On May 12, 2016, the shares registered one year high at $46.95 and the one year low was seen on Oct 6, 2015. The 50-Day Moving Average price is $44.37 and the 200 Day Moving Average price is recorded at $40.53.

Baxter International (NYSE:BAX) has tumbled 1.33% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.25% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 0.31% and the outperformance has advanced to 4.31% for the last 4 weeks period.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.